SAN FRANCISCO, July 10, 2024 /PRNewswire/ — Therapeutic supply platform Granza Bio introduced as we speak the shut of its oversubscribed $7.14M Seed led by Felicis and Refactor, together with Y Combinator and notable angel buyers.
“We found a brand new characteristic of the immune system that has the potential to remodel the therapeutic panorama” – Prof. Dustin.
Based in 2024 by a crew of most cancers and immunology researchers on the College of Oxford, Granza Bio makes use of the invention of “assault particles,” a robust suite of weapons within the immune system’s arsenal that may combat ailments akin to cancers, autoimmunity and infections.
“With assault particles, we found a brand new characteristic of the immune system that has the potential to remodel the therapeutic panorama. They provide the facility of mobile therapies with the off-the-shelf ease of antibody-based medication,” stated Granza Bio co-founder Michael Dustin, Professor of Molecular Immunology at Oxford.
Nevertheless, the crew realized they lacked an efficient supply system for packaging and delivering assault particles to particular tissues.
To unravel this downside, Granza Bio’s platform gives a novel supply system that focuses on three key areas:
1) The flexibility to ship quite a lot of cargo varieties (akin to RNAs, proteins, and assault particles)
2) The flexibility to ship to a spread of tissue websites
3) Overcoming immunological activation triggered by the supply automobile
“We’re growing a collection of precision supply shells that may embody and direct any therapeutic cargo to the proper vacation spot in our physique. This work might be elementary for turning promising discoveries in genetic drugs and most cancers therapeutics into impactful therapies for sufferers,” stated Granza co-founder and Chief Govt Officer, Dr. Ashwin Nandakumar.
“By way of the event of a complete library of engineered shells, we intention to sort out the challenges of tropism, immunogenicity, and stability head-on. Our power lies within the interdisciplinary nature of our crew, spanning elementary immunology to industrial manufacturing and scale-up processes. This can be a pivotal second for the sphere of drug supply therapeutics and we’re on the forefront of this transformation,” stated Dr. Ashwin Jainarayanan, Granza Bio’s Chief Scientific Officer.
Dr. Nandakumar, CEO, holds a PhD in Oncology, has beforehand arrange scientific trials, and brings oncology start-up expertise. Dr. Jainarayanan, CSO, is a PhD in Interdisciplinary Bioscience and was not too long ago chosen as a Schmidt Science Fellow. Prof. Dustin can also be the director of analysis on the Kennedy Institute of Rheumatology at Oxford.
“The immune system is nature’s strongest mechanism for organic remediation. By bettering the supply and specificity of naturally occurring assault particles, Granza Bio can unlock a brand new world of capabilities for oncological and immunological ailments,” stated Tobi Coker, Deal Accomplice at Felicis. “Granza encompasses a novel mixture of great scientific developments, a founding crew with complementary abilities, and deep area experience. We’re thrilled to be working with them.”
“I give attention to discovering technical founders who’re consultants of their fields and are magnets for purchasers, expertise, and buyers. Each Ashwins actually match that completely, in my view, as they construct a greater supply mechanism for quite a lot of therapeutics,” stated Zal Bilimoria, founding associate at Refactor.
The funding spherical additionally consists of participation from different buyers together with Metaplanet, Zeno Ventures, Ritual Capital, Pioneer Fund, Oxford Angel Fund, and North South Ventures. Notable angels joined the spherical together with Richard Aberman (former YC Visiting Group Accomplice), JJ Fliegelman (former YC Visiting Group Accomplice), Eric Migicovsky (former YC Group Accomplice), Eric Eldon (former editor of TechCrunch), Eli Brown (founder, Guilded), Eoghan Mccabe (founder, Intercom), Benjamin Bryant (co-founder, Earbits), Yotam Rosenbaum (co-founder, Earbits), Will Olsen (co-founder, Have interaction Bio) and Joel Meyer.
For partnership and licensing alternatives, please attain out to data@granzabio.com.
Study extra at granzabio.com.
About Granza Bio
Based in 2024, Granza Bio is a biotechnology firm growing a novel supply “shell” platform to direct therapeutic cargo to particular tissues. For his or her lead candidate, Granza Bio is leveraging the invention of the immune system’s highly effective suite of weapons, “assault particles”. Using their superior supply platform, they intention to focus on these “assault particles” towards a spread of ailments akin to most cancers, autoimmune issues, and infections. The corporate has not too long ago raised a $7M+ Seed spherical led by Felicis and Refactor, together with Y Combinator and notable ventures and angel buyers. Granza Bio was co-founded by Dr. Ashwin Nandakumar, Dr. Ashwin Jainarayanan, and Prof. Michael Dustin, researchers from the College of Oxford. Study extra at granzabio.com. Go to our linkedin.
View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/granza-bio-raises-7m-seed-funding-to-advance-the-delivery-of-cancer-treatment-and-genetic-medicines-302192267.html
SOURCE Granza Bio Company
